Will the Treatment Protocols for Schizophrenia be Changing Soon?

REFERENCES

• Angell, M. (2004). The truth about the drug companies: How they deceive us and what to do about it. New York, NY: Random House.
   Google Scholar
• Amminger, G.P., Schafer, M.R., Papageorgiou, K., Klier, C.M., Cotton, S.M., Harrigan, S.M., … Berger, G.E. (2010). Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry, 67(2), 146–154.
   PubMed Web of Science ®Google Scholar
• Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N.A., & Serhan, C.N. (2005). Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin e1. Journal of Experimental Medicine, 201, 713–722.
   PubMed Web of Science ®Google Scholar
• Ballesteros, A., Summerfelt, A., Du, X., Jiang, P., Chiappelli, J., Tagamets, M., … Hong, L.E. (2013). Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clinical Neurophysiology. doi: 10.1016/j.clinph.2013.05.021
   PubMed Web of Science ®Google Scholar
• Bartos, M., Vida, I., & Jonas, P. (2007). Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nature Reviews Neuroscience, 8(1), 45–56.
   PubMed Web of Science ®Google Scholar
• Behrens, M.M., & Sejnowski, T.J. (2009). Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology, 57(3), 193–200.
   PubMed Web of Science ®Google Scholar
• Bentley, K.J., Walsh, J., & Farmer, R.L. (2005). Social work roles and activities regarding psychiatric medication: Results of a national survey. Social Work, 50(4), 295–303.
   PubMed Web of Science ®Google Scholar
• Berger, G.E., Proffitt, T.M., McConchie, M., Yuen, H., Wood, S.J., Amminger, G. P., … McGorry, P.D. (2007). Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 68(12), 1867–1875.
   PubMed Web of Science ®Google Scholar
• Berger, G. E., Wood, S. J., Wellard, R. M., Proffitt, T. M., McConchie, M., Amminger, G. P. … McGorry, P.D. (2008). Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology, 33(10), 2467–2473.
   PubMed Web of Science ®Google Scholar
• Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., … Bush, A.I. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biological Psychiatry, 64(5), 361–368.
   PubMed Web of Science ®Google Scholar
• Bitanihirwe, B.K., Lim, M.P., Kelley, J.F., Kaneko, T., & Woo, T.U. (2009). Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry, 9, 71. doi: 10.1186/1471-244X-9-71
   PubMed Web of Science ®Google Scholar
• Bola, J.R. (2006). Medication-free research in early-episode schizophrenia: Evidence of long-term harm? Schizophrenia Bulletin, 32(2), 288–296.
   PubMed Web of Science ®Google Scholar
• Bola, J.R., Kao, D.T., & Soydan, H. (2012). Antipsychotic medications for early-episode schizophrenia. Schizophrenia Bulletin, 38(1), 23–25.
   PubMed Web of Science ®Google Scholar
• Bola, J.R., Lehtinen, K., Culberg, J., & Ciompi, L. (2009). Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: A review of the literature. Psychosis, 1(1), 4–18.
   Web of Science ®Google Scholar
• Bola, J.R., & Mosher, L.R. (2002). At issue: Predicting drug-free treatment response in acute psychosis from the Soteria project. Schizophrenia Bulletin, 28(4), 559–575.
   PubMed Web of Science ®Google Scholar
• Bola, J.R., & Mosher, L.R. (2003). Treatment of acute psychosis without neuroleptics: Two-year outcomes from the Soteria Project. Journal of Nervous and Mental Disease, 191(4), 219–229.
   PubMed Web of Science ®Google Scholar
• Brekke, J.S., Hoe, M., Long, J., & Green, M.F. (2007). How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophrenia Bulletin, 33(5), 1247–1256.
   PubMed Web of Science ®Google Scholar
• Buka, S.L., Tsuang, M.T., & Lipsitt, L.P. (1993). Pregnancy/delivery complications and psychiatric diagnosis. A prospective study. Archives of General Psychiatry, 50(2), 151–156.
   PubMed Web of Science ®Google Scholar
• Cabungcal, J.H., Steullet, P., Kraftsik, R., Cuenod, M., & Do, K.Q. (2013). Early-life insults impair parvalbumin interneurons via oxidative stress: Reversal by N-acetylcysteine. Biological Psychiatry, 73(6), 574–582.
   PubMed Web of Science ®Google Scholar
• Calarge, C.A., Zimmerman, B., Xie, D., Kuperman, S., & Schiechte, J.A. (2010). A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys, Journal of Clinical Psychiatry, 7(3), 338–347.
   Web of Science ®Google Scholar
• Cani P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., & Burcelin, R. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes, 57(6), 1470–1481.
   Web of Science ®Google Scholar
• Carmeli, C., Knyazeva, M.G., Cuenod, M., & Do, K.Q. (2012). Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS One, 7(2), e29341. doi: 10.1371/journal.pone.0029341
   PubMed Web of Science ®Google Scholar
• Casey, D.E. (2006). Implications of the CATIE trial on treatment: Extrapyramidal symptoms. CNS Spectrum, 11 ( Suppl. 7), 25–31.
   PubMed Web of Science ®Google Scholar
• Christensen, O., & Christensen, E. (1988). Fat consumption and schizophrenia. Acta Psychiatrica Scandanavia, 78(5), 587–591.
   PubMed Web of Science ®Google Scholar
• Clarke, M.C., Tanskanen, A., Huttunen, M., Leon, D.A., Murray, R.M., Jones, P.B., & Cannon, M. (2011). Increased risk of schizophrenia from additive interaction between infant motor developmental delay and obstetric complications: Evidence from a population-based longitudinal study. American Journal of Psychiatry, 168(12), 1295–1302.
   PubMed Web of Science ®Google Scholar
• Curley, A.A., Arion, D., Volk, D.W., Asafu-Adjei, J.K., Sampson, A.R., Fish, K.N., & Lewis, D.A. (2011). Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: Clinical, protein, and cell type-specific features. American Journal of Psychiatry, 168(9), 921–929.
   PubMed Web of Science ®Google Scholar
• Deo, A.J., Goldszer, I.M., Li, S., DiBitetto, J.V., Henteleff, R., Sampson, A., … Sweet, R.A. (2013). PAK1 protein expression in the auditory cortex of schizophrenia subjects. PLoS One, 8(4), e59458. doi: 10.1371/journal.pone.0059458
   Google Scholar
• Do, K.Q., Cabungcal, J.H., Frank, A., Steullet, P., & Cuenod, M. (2009). Redox dysregulation, neurodevelopment, and schizophrenia. Current Opinions in Neurobiology, 19(2), 220–230.
   PubMed Web of Science ®Google Scholar
• Dorph-Petersen, K.A., Pierri, J.N., Perel, J.M., Sun, Z., Sampson, A.R., & Lewis, D.A. (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology, 30(9), 1649–1661.
   PubMed Web of Science ®Google Scholar
• Eggan, S.M., Stoyak, S.R., Verrico, C.D., & Lewis, D.A. (2010). Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology, 35(10), 2060–2071.
   PubMed Web of Science ®Google Scholar
• Elvevag, B., & Goldberg, T.E. (2000). Cognitive impairment in schizophrenia is the core of the disorder. Critical Reviews in Neurobiology, 14(1), 1–21.
   PubMed Web of Science ®Google Scholar
• Erhardt, S., Olsson, S.K., & Engberg, G. (2009). Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs, 23(2), 91–101.
   PubMed Web of Science ®Google Scholar
• Ferder, L., Ferder, M.D., & Inserra, F. (2010). The role of high-fructose corn syrup in metabolic syndrome and hypertension. Current Hypertension Report, 12, 105–112.
   PubMed Web of Science ®Google Scholar
• Francey, S.M., Nelson, B., Thompson, A., Parker, A.G., Kerr, M., Macneil, C., Fraser, R., Hughes, F., Crisp, K., Harrigan, S., Wood, S.J., Berk, M., & McGorry, P.D. (2010). Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research, 119, 1–10.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., & Berger, G. (2012). Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology, 32(2), 179–185.
   PubMed Web of Science ®Google Scholar
• Gleeson, J.F., Cotton, S.M., Alvarez-Jimenez, M., Wade, D., Gee, D., Crisp, K., … McGorry, P.D. (2013). A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. Schizophrenia Bulletin, 39(2), 436–448.
   PubMed Web of Science ®Google Scholar
• Gotzsche, P.C. (2013). Deadly medicines and organized crime: How big pharma has corrupted healthcare. New York, NY: Radcliffe Publishing.
   Google Scholar
• Grace, A.A. (2012). Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology, 62(3), 1342–1348.
   PubMed Web of Science ®Google Scholar
• Green, M.F., & Nuechterlein, K.H. (1999). Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bulletin, 25(2), 309–319.
   PubMed Web of Science ®Google Scholar
• Gysin, R., Kraftsik, R., Sandell, J., Bovet, P., Chappuis, C., Conus, P., … Do, K.Q. (2007). Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proceedings of the National Academy of Science U S A, 104(42), 16621–16626.
   PubMed Web of Science ®Google Scholar
• Haddad, P.M., & Anderson, I.M. (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 62(11), 1649–1671.
   PubMed Web of Science ®Google Scholar
• Harrow, M., Grossman, L.S., Jobe, T.H., & Herbener, E.S. (2005). Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophrenia Bulletin, 31(3), 723–734.
   PubMed Web of Science ®Google Scholar
• Harrow, M., & Jobe, T.H. (2013). Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophrenia Bulletin, 39(5), 962–965.
   PubMed Web of Science ®Google Scholar
• Harrow, M., Jobe, T.H., & Faull, R.N. (2012). Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychological Medicine, 42(10), 2145–2155.
   PubMed Web of Science ®Google Scholar
• Heins, M., Simons, C., Lataster, T., Pfeifer, S., Versmissen, D., Lardinois, M., … Myin-Germeys, I. (2011). Childhood trauma and psychosis: a case-control and case-sibling comparison across different levels of genetic liability, psychopathology, and type of trauma. American Journal of Psychiatry, 168(12), 1286–1294.
   PubMed Web of Science ®Google Scholar
• Ho, B.C., Andreasen, N.C., Ziebell, S., Pierson, R., & Magnotta, V. (2011). Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Archives of General Psychiatry, 68(2), 128–137.
   PubMed Web of Science ®Google Scholar
• Horrobin, D.F. (2003). Omega-3 Fatty acid for schizophrenia. [CommentLetter]. American Journal of Psychiatry, 160(1), 188–189; author reply 189.
   PubMed Web of Science ®Google Scholar
• Howes, O.D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III—The final common pathway. Schizophrenia Bulletin, 35(3), 549–562.
   PubMed Web of Science ®Google Scholar
• Insel, T. (2013, August 28). Director’s blog: Antipsychotics: Taking the long view. Retrieved from http://www.nimh.nih.gov/about/director/2013/antipsychotics-taking-the-long-view.html
   Google Scholar
• Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J.E., Day, R., & Bertelsen, A. (1992). Schizophrenia: manifestations, incidence and course in different cultures. [Monograph supplement]. Psychological Medicine, 20, 1–97.
   Google Scholar
• Johnstone, E.C., Macmillan, J.F., Frith, C.D., Benn, D.K., & Crow, T.J. (1990). Further investigation of the predictors of outcome following first schizophrenic episodes. British Journal of Psychiatry, 157, 182–189.
   PubMed Web of Science ®Google Scholar
• Kantrowitz, J.T., Hoptman, M.J., Leitman, D.I., Silipo, G., & Javitt, D.C. (2013). The 5% difference: Early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder. Psychological Medicine, April 24, 1–12. doi: 10.1017/S0033291713000834
   Google Scholar
• Kantrowitz, J.T., & Javitt, D.C. (2010). N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Research Bulletin, 83(3–4), 108–121.
   PubMedGoogle Scholar
• Karry, R., Klein, E., & Ben Shachar, D. (2004). Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biological Psychiatry, 55(7), 676–684.
   PubMed Web of Science ®Google Scholar
• Kinney, J.W., Davis, C.N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M.M. (2006). A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. Journal of Neuroscience, 26(5), 1604–1615.
   PubMed Web of Science ®Google Scholar
• Konopaske, G.T., Dorph-Petersen, K.A., Pierri, J.N., Wu, Q., Sampson, A.R., & Lewis, D.A. (2007). Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology, 32(6), 1216–1223.
   PubMed Web of Science ®Google Scholar
• Konopaske, G.T., Dorph-Petersen, K.A., Sweet, R.A., Pierri, J.N., Zhang, W., Sampson, A.R., & Lewis, D.A. (2008). Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biological Psychiatry, 63(8), 759–765.
   PubMed Web of Science ®Google Scholar
• Labrie, V., & Roder, J.C. (2010). The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neuroscience and Biobehaviral Reviews, 34(3), 351–372.
   PubMed Web of Science ®Google Scholar
• Lagnado, L. (2013, August 11). U.S. probes use of antipsychotic drugs on children. Wall Street Journal. Retrieved from http://online.wsj.com/article_email/SB100014241278873234776045786541308654130865747470
   Google Scholar
• Lavoie, S., Murray, M.M., Deppen, P., Knyazeva, M.G., Berk, M., Boulat, O., … Do, K.Q. (2008). Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology, 33(9), 2187–2199.
   PubMed Web of Science ®Google Scholar
• Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J.M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet, 379(9831), 2063–2071.
   PubMed Web of Science ®Google Scholar
• Marchbanks, R.M., Ryan, M., Day, I.N., Owen, M., McGuffin, P., & Whatley, S.A. (2003). A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophrenia Research, 65(1), 33–38.
   PubMed Web of Science ®Google Scholar
• Marshall, M., & Rathbone, J. (2011). Early intervention for psychosis. Schizophrenia Bulletin, 37(6), 1111–1114.
   PubMed Web of Science ®Google Scholar
• Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry, 62(9), 975–983.
   PubMed Web of Science ®Google Scholar
• McGorry, P., Alvarez-Jimenez, M., & Killackey, E. (2013). Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry, 70, 898–899.
   Web of Science ®Google Scholar
• McGrath, J.J., Burne, T.H., Feron, F., Mackay-Sim, A., & Eyles, D.W. (2010). Developmental vitamin D deficiency and risk of schizophrenia: A 10-year update. Schizophrenia Bulletin, 36(6), 1073–1078.
   PubMed Web of Science ®Google Scholar
• Meyer, U., Schwarz, M.J., & Muller, N. (2011). Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacological Therapy, 132(1), 96–110.
   PubMed Web of Science ®Google Scholar
• Milev, P., Ho, B.C., Arndt, S., & Andreasen, N.C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry, 162(3), 495–506.
   PubMed Web of Science ®Google Scholar
• Mittal, V.A., Ellman, L.M., & Cannon, T.D. (2008). Gene-environment interaction and covariation in schizophrenia: The role of obstetric complications. Schizophrenia Bulletin, 34(6), 1083–1094.
   PubMed Web of Science ®Google Scholar
• Peet, M. (2004). Nutrition and schizophrenia: Beyond omega-3 fatty acids. Prostaglandins Leukotrieneand Essential Fatty Acids, 70(4), 417–422.
   PubMed Web of Science ®Google Scholar
• Peet, M., Brind, J., Ramchand, C.N., Shah, S., & Vankar, G.K. (2001). Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research, 49(3), 243–251.
   PubMed Web of Science ®Google Scholar
• Perkins, D.D., Gu, H., Boteva, K., Lieberman, J. A. (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. American Journal of Psychiatry, 162(10), 1785–1804.
   PubMed Web of Science ®Google Scholar
• Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., & Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biological Psychiatry, 63(8), 801–808.
   PubMed Web of Science ®Google Scholar
• Powell, S.B., Sejnowski, T.J., & Behrens, M.M. (2012). Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia. Neuropharmacology, 62(3), 1322–1331.
   PubMed Web of Science ®Google Scholar
• Pramyothin, P., & Khaodhiar, L. (2010). Metabolic syndrome with the atypical antipsychotics. Current Opinion in Endocrinology, Diabetes & Obesity, 17(5), 460–466.
   PubMed Web of Science ®Google Scholar
• Samaha, A.N., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007). “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. Journal of Neuroscience, 27(11), 2979–2986.
   PubMed Web of Science ®Google Scholar
• Schwartz, M., & Schechter, R. (2011). Systemic inflammatory cells fight off neurodegenerative disease. Nature Reviews: Neurology, 6, 405–410.
   Web of Science ®Google Scholar
• Seeman, P., Weinshenker, D., Quirion, R., Srivastava, L. K., Bhardwaj, S. K., Grandy, D. K., … Tallerico, T. (2005). Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proceedings of the National Academy of Sciences U S A, 102(9), 3513–3518.
   PubMed Web of Science ®Google Scholar
• Seikkula, J., & Olson, M.E. (2003). The open dialogue approach to acute psychosis: Its poetics and micropolitics. Family Process, 42(3), 403–418.
   PubMed Web of Science ®Google Scholar
• Seikkula, J., Alakare, B., & Aaltonen, J. (2011). Long-term stability of acute psychosis outcomes in advanced community care: The western Lapland Project. Psychosis, 3, 1–13.
   Web of Science ®Google Scholar
• Snyder, M.A., & Gao, W.J. (2013). NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Frontiers in Cellular Neuroscience, 7, 31. doi: 10.3389/fncel.2013.00031
   PubMed Web of Science ®Google Scholar
• Sorensen, H.J., Mortensen, E.L., Schiffman, J., Reinisch, J.M., Maeda, J., & Mednick, S.A. (2010). Early developmental milestones and risk of schizophrenia: a 45-year follow-up of the Copenhagen Perinatal Cohort. Schizophrenia Research, 118(1–3), 41–47.
   PubMed Web of Science ®Google Scholar
• Steingard, S. (2013, December 9). A psychiatrist thinks some patients are better off without antipsychotic drugs. Washington Post. Retrieved from http://www.washingtonpost.com/national/health-science/a-psychiatrist-things-some-patients-are-better-off-without-antipsychotic-drugs
   Google Scholar
• Steullet, P., Cabungcal, J.H., Kulak, A., Kraftsik, R., Chen, Y., Dalton, T.P., … Do, K.Q. (2010). Redox dysregulation affects the ventral but not dorsal hippocampus: Impairment of parvalbumin neurons, gamma oscillations, and related behaviors. Journal of Neuroscience, 30(7), 2547–2558.
   PubMed Web of Science ®Google Scholar
• Steullet, P., Neijt, H.C., Cuḗnod, & Do, K.Q. (2006). Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience, 130, 807–819.
   Google Scholar
• Sullivan, P.F. (2005). The genetics of schizophrenia. PLoS Medicine, 2(7), e212. doi: 10.1371/journal.pmed.0020212
   PubMed Web of Science ®Google Scholar
• Thompson, A., Nelson, B., & Yung, A. (2011). Predictive validity of clinical variables in the “at risk” for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study. Schizophrenia Research, 126(1–3), 51–57.
   PubMed Web of Science ®Google Scholar
• Tsai, G.E., & Lin, P.Y. (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Current Pharmaceutical Design, 16(5), 522–537.
   PubMed Web of Science ®Google Scholar
• van Os, J., & Kapur, S. (2009). Schizophrenia. Lancet, 374(9690), 635–645.
   PubMed Web of Science ®Google Scholar
• Verge, B., Alonso, Y., Valero, J., Miralles, C., Vilella, E., & Martorell, L. (2011). Mitochondrial DNA (mtDNA) and schizophrenia. European Psychiatry, 26(1), 45–56.
   PubMed Web of Science ®Google Scholar
• Volk, D.W., & Lewis, D.A. (2013). Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia. Neuroscience, 248C, 154–164.
   PubMed Web of Science ®Google Scholar
• Walker, E.F., Lewine, R.R., & Neumann, C. (1996). Childhood behavioral characteristics and adult brain morphology in schizophrenia. Schizophrenia Research, 22(2), 93–101.
   PubMed Web of Science ®Google Scholar
• Wunderink, L., Nieboer, R.M., Wiersma, D., Sytema, S., & Nienhuis, F.J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 70, 913–920.
   PubMed Web of Science ®Google Scholar
• Ziv, Y., & Schwartz, M. (2008). Immune-based regulation of adult neurogenesis: Implications for learning and memory. Brain, Behavior, and Immunity, 22, 167–176.
   PubMed Web of Science ®Google Scholar